⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

Official Title: Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations

Study ID: NCT00897247

Study Description

Brief Summary: RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite.

Detailed Description: OBJECTIVES: * Identify patients with known asbestos exposure at early stages of disease development (i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural mesothelioma). * Determine the expression levels of tumor-associated proteins in these patients. * Analyze samples of serum and pleural effusions obtained from these patients. * Determine the proteomic profile of samples obtained from these patients. * Determine the molecular mechanisms associated with the regulation of the extracellular matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix metalloproteins) involved in disease onset and progression. OUTLINE: This is a multicenter study. Patients undergo collection of body cavity fluid, including pleural effusion, and blood. Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available, are analyzed for proteomic profile, gene expression profile, and tumor-associated protein expression levels. PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.

Eligibility

Minimum Age: 25 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Contact Details

Name: Anil Wali, PhD

Affiliation: Barbara Ann Karmanos Cancer Institute

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: